Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634409 · ClinicalTrials.gov registry record · Phase 2
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
A Phase 2 study of COVID-19, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,755
- Enrollment target
- 20
- Study locations
NCT04634409 is a Phase 2 study of COVID-19 that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,755 participants, below the 55,206-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT04634409, a Phase 2 study of COVID-19, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,755 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bamlanivimab
- DRUG Etesevimab
- DRUG VIR-7831
- DRUG Bebtelovimab
Study Locations (20)
California
- Smart Cures Clin Research - Anaheim
- Hope Clinical Research - Canoga Park
- VCT-Covina - Covina
- Neighborhood Healthcare - Escondido
- Chemidox Clinical Trials - Lancaster
- Ark Clinical Research - Long Beach
- Long Beach Clinical Trials LLC - Long Beach
- Cedars Sinai Medical Center - Los Angeles
- Central Valley Research, LLC - Modesto
- Inland Empire Liver Foundation - Rialto
- Sutter Institute For Medical Research - Sacramento
- Wolverine Clinical Trials, LLC - Santa Ana
Arizona
- The Institute for Liver Health - Mesa
- Perseverance Research Center - Scottsdale
- CRI of Arizona, LLC - Sun City West
- Fiel Family and Sports Medicine PC - Tempe
- The Institute for Liver Health - Tucson
Arkansas
- KLR Business Group, Inc. dba Arkansas Clinical Research - Little Rock
- Applied Rsch Ctr - Arkansas Inc. - Little Rock
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,755 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2021-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634409
The ClinicalTrials.gov registry entry for NCT04634409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,755 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,206-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT04634409 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04634409 about?
NCT04634409 is a clinical study titled "A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness". The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much viru...
What is the current status of trial NCT04634409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,755 participants. The study started on 2020-10-29. Estimated completion is 2021-10-18.
What conditions does trial NCT04634409 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04634409?
The interventions under investigation include: Placebo (DRUG), Bamlanivimab (DRUG), Etesevimab (DRUG), VIR-7831 (DRUG), Bebtelovimab (DRUG).
Who is sponsoring clinical trial NCT04634409?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04634409 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.